What is the success rate of stem cell therapy for Macular Degeneration & Vision?
A reliable success rate for retinal cell therapy is not established. Inherited retinal disease and age-related macular degeneration are different conditions, and visual acuity, field, sensitivity, anatomy and safety are distinct endpoints. Small uncontrolled cohorts cannot predict an individual's chance of stabilised or improved vision. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
What the evidence shows for Macular Degeneration & Vision
Human retinal cell-therapy studies are early and heterogeneous, involving different diseases, cell products, surgical routes and endpoints. Small-cohort safety observations and exploratory visual changes do not establish durable vision stabilisation or restoration. Imaging, light sensitivity and visual-acuity measures should not be merged into a single response claim. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
Am I a candidate? → · Macular Degeneration & Vision: full overview → · Macular Degeneration & Vision cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Macular Degeneration & Vision: cell-therapy evidence and registered trials
- How much does stem cell therapy for Macular Degeneration & Vision cost? (2026)
- Macular Degeneration & Vision stem cell therapy — your questions answered (2026)
- Macular Degeneration & Vision: cell-therapy evidence by therapy class